Compare Stanley Black & Decker, Inc. (SWK) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stanley Black & Decker, Inc. vs TG Therapeutics Inc — how do they compare? Stanley Black & Decker, Inc. trades at $91.6 (market cap $14.17B), while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: Stanley Black & Decker, Inc. is the larger of the two by market cap, and Stanley Black & Decker, Inc. pays a 3.58% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SWK | TGTX | |
|---|---|---|
Market Cap | $14.17B | $8.53B |
52-Week High | $104.00 | $59.06 |
52-Week Low | $62.12 | $26.94 |
Enterprise Value | $18.33B | $8.74B |
Dividend Yield | 3.58% | — |
Sector | — | Health |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stanley Black & Decker (SWK) trades at $93.81, down 3.65% on the day, with a bearish technical signal from moving averages and oscillators. The company reported three consecutive quarterly earnings beats, with Q3 2026 results pending. Recent portfolio refinement includes the sale of Excel Industries to Bad Boy Mowers. Valuation metrics show a P/E of 22.94 and P/S of 0.93, with a net income margin of 4.07% for 2025.
The outlook is mixed: analyst consensus is a $98.50 price target with 43% buy ratings, but technical indicators suggest near-term pressure. Opportunities include cost transformation benefits and dividend stability, while risks involve debt levels and industrial demand volatility. The stock's current price is near the low end of analyst targets, indicating potential upside if fundamentals strengthen.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
